United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

US pharmaceutical giant Pfizer expects the coronavirus vaccine it developed with BioNTech, the first to be authorized for emergency use in the West, to make it about $15 billion in revenues in 2021. The company expects to produce up to 2 billion doses of the vaccine in 2021, based on its updated six-dose label, it said Tuesday. By January 31, it had already supplied 65 million doses of its vaccine globally, with close to half going to the US.

Pfizer expects to make $15 billion in sales from its COVID-19 vaccine in 2021

Shares of Pfizer (NYSE:PFE) fell 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 23.64% over the past year to $0.42, which missed the estimate of $0.48.

Pfizer: Q4 Earnings Insights

Shares of Pfizer Inc. slipped 0.6% in premarket trading Tuesday, after the drug maker reported fourth-quarter profit that missed expectations, but revenue that beat forecasts and provided an upbeat full-year outlook. The company swung to net income of $594 million, or 10 cents a share, from a net loss of $337 million, or 6 cents a share, in the year-ago period.

Pfizer stock slips after profit misses expectations, while revenue beats

Pfizer also raised its full-year earnings guidance to between $3.10 to $3.20 from $3 to $3.10, citing “additional refinements” of its vaccine revenue forecast.

Pfizer expects about $15 billion in 2021 sales from Covid vaccine

Pfizer Inc on Tuesday forecast sales of about $15 billion from the coronavirus vaccine that it is making along with German partner BioNTech.

Pfizer sees about $15 billion in 2021 sales from COVID-19 vaccine

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter 2020 and full-year 2020, raised 2021 guidance(4) for Adjusted diluted EPS(2) and provided 2021 financial guidance(4) for other Adjusted(2) income statement line items, including details regarding the expected contributions to 2021 performance from BNT162b2, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2020

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS

Delaying the second dose of the Pfizer jab – the current government strategy - may leave some elderly patients at risk of infection by the South African variant, new research suggests.

Delaying second dose of Pfizer COVID jab may leave elderly at risk, new study suggests

Will Pfizer's Latest Bad News Wipe Out a Big Chunk of Its COVID Vaccine Profits?

AbbVie

AstraZeneca

Gilead Sciences

Viatris

Bristol-Myers

Merck

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipelines appeared first on InvestorPlace.

7 Pharmaceutical Stocks With Compelling Pipelines

The vaccine will be a key. But there are other growth drivers for Pfizer stock.

3 Reasons Pfizer Stock Will Have a Solid 2021

German chancellor Angela Merkel set to hold crisis talks on Monday to boost faltering vaccination program

BioNTech-Pfizer partnership pledges 75 million more vaccine doses to help ease the EU bloc's shortage

Amazon

Alibaba

Chipotle

Cirrus Logic

Ford Motor Company

Alphabet

ON Semiconductor

QUALCOMM

T-Mobile US

Vertex Pharmaceuticals

Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.

Another Big Week for Q4 Earnings, Econ News; ON Semi Beats

Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

Pfizer (NYSE:PFE) announces its next round of earnings this Tuesday, February 02. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

Pfizer Earnings Preview

Abbott Labs

Teladoc

Companies working to bring us to the other side of the pandemic might be the biggest winners.

3 Mega-Trends Healthcare Investors Should Watch Right Now

Exxon Mobil

It's another busy week for earnings, with results from Alphabet, Amazon, Alibaba, Electronic Arts, Exxon Mobil, Pfizer, T-Mobile, Ford, and many more. Plus, the January jobs report.

Amazon, Exxon Mobil, Pfizer, Alphabet, and Other Stocks to Watch This Week

Amgen

Biogen

Alexion Pharma

Regeneron Pharmaceuticals

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week

Johnson & Johnson

Moderna

Novavax

Which Is the Best COVID Vaccine Stock: Pfizer, BioNTech, Moderna, Johnson & Johnson, or Novavax?

With 2020's proof in hand, it won't razzle dazzle Wall Street, but make no mistake, Pfizer stock can breathe life into investors portfolios The post Now More Than Ever Why Pfizer Stock Is a Buy appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner It doesn't matter if you have $500 in savings or $5 million.

Now More Than Ever Why Pfizer Stock Is a Buy

Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".

Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings

New strains represent a challenge now and into the future.

Here's What You Need to Know About New COVID Strains -- and How Today's Vaccines Are Holding Up

Doses still are scarce in some locations.

Should Investors Worry About Coronavirus Vaccine Supply?

Pfizer already is putting its COVID-19 vaccine into people's arms, while Johnson & Johnson's is waiting to be approved.

Better Coronavirus Stock: Johnson & Johnson vs. Pfizer

In the healthcare industry, diligence is a matter of life and death. We're looking at you, Theranos.

Here's What Investors Need to Know About Medical Diligence

The small biotech just reported terrific news for its COVID-19 vaccine candidate.

News for Pfizer Stock (PFE)